Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split

HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, announced that it expects to implement a 1-for-20 reverse stock split, or consolidation of its issued and unissued Class A ordinary shares and Class B ordinary shares, par value $0.001 per share (the “Ordinary Shares”), effective at the opening of market of October 26, 2026 (the “Reverse Stock Split”). Trading in the Class A Ordinary Shares on a split-adjusted basis will continue on Nasdaq on October 26, 2026 under the symbol “HKPD.” The new CUSIP number for the Company’s Ordinary Shares post-Reverse Stock Split is G6365B112.

Upon the effectiveness of the Reverse Stock Split, every twenty issued and outstanding Ordinary Shares will be consolidated into one Ordinary Shares. The Company’s Ordinary Shares have a par value of $0.001 per share prior to the Reverse Stock Split and will have a par value of $0.02 per share following the Reverse Stock Split. Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share at a participant level. The Reverse Stock Split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding Ordinary Shares, except for adjustments that may result from the treatment of fractional shares. The Reserves Stock Split was approved by the Company’s board of directors.